Press release Communiqué de presse
Press release Communiqué de presse
February 28, 2013 28 February, 2013
Sernova and Centre for Commercialization of Regenerative Medicine Partner To Treat Chronic Diseases
February 28, 2013 (TORONTO and LONDON,
ON) -- The
Centre for Commercialization of Regenerative
Medicine
(CCRM) is pleased to announce the addition of
Sernova
Corp. ("Sernova" or the "Company") (TSX
VENTURE: SVA
- News) to its member-based industry
consortium.
Sernova's combination of immuno-protective
technology
and therapeutic cells for the treatment of chronic
diseases
advances CCRM's goal of developing innovative
cell-
based product.
"Sernova's technology for transplanting
therapeutic cells
into an implanted medical device for the
treatment of
diabetes and other chronic diseases goes hand-
in-hand
with our strategy of translating cell-based
medical
discoveries into commercial products and
therapies," says
Dr. Michael May, CEO of CCRM. "Sernova's
expertise in
the area of cell therapy will bring great value to
CCRM's
core development platforms and to other
consortium
members."
CCRM is working with its industry consortium to
address
real-life bottlenecks in cell-based product
pipelines. Its
industry consortium now numbers over 20
members.
These companies represent the key sectors of
the
industry: therapeutics, devices, reagents, and
cells as
tools.
"Becoming a member of CCRM offers the
opportunity for
further validation for our technology and
demonstrates our
company's commitment to the advancement of
our Cell
Pouch System(tm) as an effective, safe, long-
term and
convenient therapeutic option for the treatment
of chronic
diseases," says Dr. Philip Toleikis, President and
CEO of
Sernova Corp. "We will work together with the
other
consortium members to achieve CCRM's
objectives in
treating and managing devastating diseases
such as
diabetes."
CCRM has built three core development
platforms: cell
reprogramming and engineering; cell
manufacturing; and,
biomaterials and devices to carry out projects
commissioned by academia and industry. CCRM
has a
fully resourced, 6,000 square foot development
facility
where all development work takes place.
Please visit www.ccrm.ca/industry-consortium to
see a
complete list of CCRM's members.
About the Centre for Commercialization of
Regenerative
Medicine (CCRM)
CCRM, a Canadian not-for-profit organization
funded by
the Government of Canada's Networks of
Centres of
Excellence program and six academic partners,
supports
the development of technologies that accelerate
the
commercialization of stem cell- and biomaterials-
based
technologies and therapies. A network of
academics,
industry and entrepreneurs, CCRM aims to
translate
scientific discoveries into marketable products for
patients.
CCRM launched in Toronto's Discovery District
on June
14, 2011.
About Sernova
Sernova Corp. is a clinical stage health-sciences
company
focused on commercializing medical
technologies.
Sernova is currently developing a platform
technology for
a number of serious disease indications, starting
with a
novel treatment for insulin-dependent diabetes,
using the
novel Cell Pouch System(TM) for transplantation
and long-
term survival of therapeutic cells and its patented
Sertolin(TM) cell technology, which can provide
an
immune-protected local environment for
therapeutic cells.
For more information on CCRM, please contact:
Stacey Johnson
Manager, Communications
Centre for Commercialization of Regenerative
Medicine
647-309-1830
stacey.johnson@ccrm.ca
www.ccrm.ca
For further information on Sernova, please
contact:
Philip Toleikis, Ph.D., President and CEO
Tel: (604) 961-2939
info@sernova.com
www.sernova.com
Tony Russo, Ph.D.
Russo Partners, LLC
Tel: (212) 845-4251
tony.russo@russopartnersllc.com